Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

This trial tests a new CAR-T cell therapy (CBG166) for people with advanced liver cancer (hepatocellular carcinoma). CAR-T therapy takes a patient's own immune cells, engineers them to attack cancer cells that have a protein called GPC3, and infuses them back into the patient. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced liver cancer (BCLC stage B or C) that cannot be surgically removed - You have already tried at least one systemic treatment (such as targeted therapy or immunotherapy) and your cancer has progressed - You are in acceptable general health and your liver is functioning reasonably well **You may NOT be eligible if...** - Your tumors are completely removable by surgery or you are eligible for a liver transplant - You are pregnant or breastfeeding - You have a serious active infection - You have been on high-dose steroids recently - You are currently receiving other immunosuppressive therapies Talk to your doctor to see if this trial is right for you.